[Featured Stock] Cellivery, Parkinson's Disease Treatment New Drug Technology Transfer Expected... 'Total Contract Size Notification Pending'

[Asia Economy Reporter Hyungsoo Park] Cellivery is soaring. On the 15th, at the JP Morgan Healthcare Conference held in San Francisco, USA, meetings with multiple global pharmaceutical companies including Takeda Pharmaceutical appear to have influenced the stock price due to increased possibilities of technology export.

At 11:16 AM on the 17th, Cellivery was trading at 77,300 KRW, up 21.92% from the previous day.

Cellivery announced that it has been negotiating and specifically adjusting contract details with an Asian pharmaceutical company to apply its drug delivery technology 'TSDT' to the development of gene interference therapeutics. Gene interference therapeutics are drugs that suppress the expression of genes causing diseases or the production of proteins.

The company discussed a 'Comprehensive Research Collaboration Agreement (MCA)' granting rights to apply TSDT to various pharmacological substances with a European pharmaceutical company. A company official stated, "Before signing the large-scale MCA contract, we received a proposal to sequentially apply TSDT to candidate substances held by that pharmaceutical company, and we are positively reviewing it."

They also held a meeting with Japan's Takeda Pharmaceutical, with whom they are jointly developing a treatment for ataxia. Cellivery and Takeda Pharmaceutical are conducting research and development applying TSDT to new drug candidates for ataxia in three phases. Currently, they have completed phase 2 and are in phase 3, evaluating drug efficacy on disease animal models. A company official said, "The results of phase 3 will be the benchmark that determines technology export and equity investment for the candidate substances and TSDT."

The pancreatic cancer treatment 'iCP-SOCS' is currently under review for primate safety evaluation reports at China's Qilu Pharmaceutical. Cellivery completed toxicokinetic analysis at a preclinical institution in Spain last October. The European pharmaceutical company negotiating technology export for the Parkinson's disease treatment 'iCP-Parkin' is expected to present the total technology transfer amount including the contract payment to Cellivery after its board meeting.

Cellivery has discussed new partnerships with several multinational pharmaceutical companies including Roche, and decided to lead concrete and feasible cooperation through direct visits after the conference.